# US 2012/0252777 A1 · Thiazolopyrimidine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252777 A1
- Document ID: US20120252777A1
- Status: Published application
- Kind: A1
- Application number: 13/429,484
- Filed: 2012-03-26
- Published: 2012-10-04
- Earliest claimed: 2011-03-28
- Assignees: Hoffmann-La Roche Inc.
- Inventors: Johannes Cornelius Hermann; Lee Edwin Lowrie, JR.; Matthew C. Lucas; Kin-Chun Thomas Luk; Fernando Padilla; Jutta Wanner; Wenwei Xie; Xiaohu Zhang
- Web page: https://patentgrep.com/patent/US20120252777A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of novel pyrrolopyrazine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

## Claims

### Claim 1

A compound of Formula I
wherein:
R1 is phenyl, optionally substituted with one or more lower alkyl, lower haloalkyl, hydroxy, hydroxy lower alkyl, lower alkoxy, lower alkyl sulfonyl, halo, nitro, amino, aminoalkyl, amido, cyano, oxo, or R1′;
R1′ is heterocycloalkyl or spiro heterocycloalkyl, each optionally substituted with one or more R1″;
R1″ is hydroxy, halo, lower alkyl, lower alkoxy, or lower haloalkyl;
B is phenyl, pyridinyl, pyrrolidinyl, or piperidinyl;
X is OH, lower alkoxy, NHC(═O)Y, C(═O)NH2, C(═O)NHY, C(═O)X′, C(═O)Y, CH2NHY, CH2CH2Y, CF═CHY, CH═CHY, CH2OH, C(═O)NHCH2CH2N(CH3)2, or C(═O)NHCH2CH2Y;
X′ is OH or lower alkoxy;
Y is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with one or more Y3;
Y3 is hydroxy, lower alkyl, lower alkoxy, halo, oxo, lower haloalkyl, hydroxy lower alkyl, amino, amido, C(═O)NH(CH3), C(═O)OH, C(═O)OY4, or heteroaryl optionally substituted by with one or more lower alkyl, oxo or SH;
Y4 is lower alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 of Formula I
wherein:
R1 is phenyl, optionally substituted with one or more lower alkyl, lower haloalkyl, hydroxy, hydroxy lower alkyl, lower alkoxy, lower alkyl sulfonyl, halo, nitro, amino, aminoalkyl, amido, cyano, oxo, or R1′;
R1′ is heterocycloalkyl or spiro heterocycloalkyl, each optionally substituted with one or more R1″;
R1″ is hydroxy, halo, lower alkyl, lower alkoxy, or lower haloalkyl;
B is phenyl, pyrrolidinyl, or piperidinyl;
X is OH, NHC(═O)Y, C(═O)NH2, C(═O)NHY, C(═O)X′, C(═O)Y, CH2NHY, CH2CH2Y, CF═CHY, CH═CHY, CH2OH, C(═O)NHCH2CH2N(CH3)2, or C(═O)NHCH2CH2Y;
X′ is OH or lower alkoxy;
Y is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with one or more Y3;
Y3 is hydroxy, lower alkyl, lower alkoxy, halo, oxo, lower haloalkyl, hydroxy lower alkyl, amino, amido, C(═O)OH, or C(═O)OY4;
Y4 is lower alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein B is phenyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein B is pyrrolidinyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein B is piperidinyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein X is NHC(═O)Y, C(═O)NH2, C(═O)NHY, C(═O)X′, C(═O)Y, C(═O)NHCH2CH2N(CH3)2, or C(═O)NHCH2CH2Y.

### Claim 7 (depends on 1)

The compound of claim 1, wherein X is NHC(═O)Y, C(═O)NHY, CH2NHY or CH2OH.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R1 is 3,4-dimethoxy-phenyl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein Y is phenyl optionally substituted with one or more Y3.

### Claim 10 (depends on 1)

The compound of claim 1, wherein Y is heteroaryl optionally substituted with one or more Y3.

### Claim 11 (depends on 1)

The compound of claim 1, wherein Y is heterocycloalkyl optionally substituted with one or more Y3.

### Claim 12 (depends on 1)

The compound of claim 1, wherein said compound is selected from the group consisting of:
3-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-benzoic acid;
[1,4]Diazepan-1-yl-{3-[7-(3,4-dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-phenyl}-methanone;
3-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(4-(methylcarbamoyl)phenyl)benzamide;
4-{3-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-benzoylamino}-benzoic acid;
4-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-ylcarbamoyl)benzoic acid;
4-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidin-3-ylcarbamoyl)benzoic acid;
4-({1-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-piperidine-3-carbonyl}-amino)-benzoic acid;
N-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-yl)-2-oxoindoline-6-carboxamide;
4-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-ylcarbamoyl)-2-hydroxybenzoic acid;
4-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-ylcarbamoyl)-2-methoxybenzoic acid;
N-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-yl)-1H-indazole-6-carboxamide;
N-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-yl)pyrazine-2-carboxamide;
6-Amino-N-{1-[7-(3,4-dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-pyrrolidin-3-yl}-nicotinamide;
N-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide;
3-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-N-[4-(5-mercapto-[1,3,4]oxadiazol-2-yl)-phenyl]-benzamide;
4-(3-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)benzamido)-2-methoxybenzoic acid;
3-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-N-[4-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenyl]-benzamide;
3-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-N-(1H-indazol-5-yl)-benzamide;
3-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-N-(1H-indazol-6-yl)-benzamide;
4-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-N-(2-pyridin-4-yl-ethyl)-benzamide;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(2-(2-oxo-1,2-dihydropyridin-4-yl)ethyl)piperidine-4-carboxamide;
4-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(2-(2-oxo-1,2-dihydropyridin-4-yl)ethyl)benzamide;
4-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-N-[2-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-ethyl]-benzamide;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(2-(pyridin-4-yl)ethyl)piperidine-3-carboxamide;
Methyl 3-(7-(3-(methylsulfonyl)phenylamino)thiazolo[5,4-d]pyrimidin-5-yl)benzoate;
3-[7-(3-Methanesulfonyl-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-benzoic acid;
3-{7-[3-(2-Methoxymethyl-pyrrolidin-1-yl)-phenylamino]-thiazolo[5,4-d]pyrimidin-5-yl}-benzoic acid;
tert-Butyl 4-(3-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)benzylamino)benzoate;
4-(3-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)benzylamino)benzoic acid;
4-((E)-2-{3-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-phenyl}-2-fluoro-vinyl)-benzoic acid;
(E)-4-(3-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)styryl)benzoic acid;
4-(3-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)phenethyl)benzoic acid;
3-{7-[(1R,5S)-3-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-phenylamino]-thiazolo[5,4-d]pyrimidin-5-yl}-benzoic acid;
N-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-yl)-1H-indazole-5-carboxamide;
(S)—N-(3-(2-Methylpyrrolidin-1-yl)phenyl)-5-(3-((piperidin-4-ylamino)methyl)phenyl)thiazolo[5,4-d]pyrimidin-7-amine;
N5-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-yl)pyridine-2,5-dicarboxamide;
Methyl 5-(1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-ylcarbamoyl)picolinate;
5-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-ylcarbamoyl)picolinic acid;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(2-oxoindolin-5-yl)piperidine-3-carboxamide;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(1H-indazol-5-yl)piperidine-3-carboxamide;
5-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidine-3-carboxamido)picolinic acid;
4-({1-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-piperidine-3-carbonyl}-amino)-2-methoxy-benzoic acid;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)piperidine-3-carboxamide;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(1H-indazol-6-yl)piperidine-3-carboxamide;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(1-oxoisoindolin-5-yl)piperidine-3-carboxamide;
4-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidine-3-carboxamido)-2-hydroxybenzoic acid;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(5-oxopyrrolidin-3-yl)piperidine-3-carboxamide;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(pyrazin-2-yl)piperidine-3-carboxamide;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(1,3-dioxoisoindolin-5-yl)piperidine-3-carboxamide;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(4-(5-mercapto-1,3,4-oxadiazol-2-yl)phenyl)piperidine-3-carboxamide;
1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(4-(5-mercapto-4-methyl-4H-1,2,4-triazol-3-yl)phenyl)piperidine-3-carboxamide;
3-{7-[3-(2-Oxa-6-aza-spiro[3.3]hept-6-yl)-phenylamino]-thiazolo[5,4-d]pyrimidin-5-yl}-benzoic acid;
4-(1-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidine-3-carboxamido)benzoic acid;
4-(1-(7-(5,6-Dimethoxypyridin-2-ylamino)thiazolo[5,4-d]pyrimidin-5-yl)pyrrolidin-3-ylcarbamoyl)benzoic acid;
Methyl 3-(7-(3-(trifluoromethyl)phenylamino)thiazolo[5,4-d]pyrimidin-5-yl)benzoate;
3-[7-(3-Trifluoromethyl-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-benzoic acid;
3-[7-(3,4,5-Trimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-benzamide;
1-(7-(3-((S)-2-Methylpyrrolidin-1-yl)phenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidin-3-ol;
4-{7-[3-Methoxy-5-((S)-2-methyl-pyrrolidin-1-yl)-phenylamino]-thiazolo[5,4-d]pyrimidin-5-yl}-benzamide;
(S)-5-(6-Methoxypyridin-3-yl)-N-(3-(2-methylpyrrolidin-1-yl)phenyl)thiazolo[5,4-d]pyrimidin-7-amine;
4-{7-[3-((S)-2-Methyl-pyrrolidin-1-yl)-phenylamino]-thiazolo[5,4-d]pyrimidin-5-yl}-benzamide;
3-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-N-[4-(2,4-dioxo-thiazolidin-5-yl)-phenyl]-benzamide;
4-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-benzamide;
(S)—N-(2-(Dimethylamino)ethyl)-4-(7-(3-(2-methylpyrrolidin-1-yl)phenylamino)thiazolo[5,4-d]pyrimidin-5-yl)benzamide;
4-(7-(3,4-Dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(2-(dimethylamino)ethyl)benzamide;
{3-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-phenyl}-methanol; and
3-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-benzamide.

### Claim 13 (depends on 1)

A method for treating an inflammatory or autoimmune condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 14 (depends on 13)

The method of claim 13, further comprising administering an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, or an agent for treating immunodeficiency disorders.

### Claim 15 (depends on 1)

A method for treating an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 16 (depends on 1)

A method for treating rheumatoid arthritis comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 17 (depends on 1)

A method for treating asthma comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 18 (depends on 1)

A method for treating an immune disorder including lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes, complications from organ transplants, xeno transplantation, diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, and Leukemia, comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 19 (depends on 1)

A method for treating an inflammatory condition comprising co-administering to a patient in need thereof a therapeutically effective amount of an anti-inflammatory compound in combination with the compound of claim 1.

### Claim 20 (depends on 1)

A method for treating an immune disorder comprising co-administering to a patient in need thereof a therapeutically effective amount of an immunosuppressant compound in combination with the compound of claim 1.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, admixed with at least one pharmaceutically acceptable carrier, excipient or diluent.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, further comprising an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, and an agent for treating immunodeficiency disorders.
